THE EFFECTS OF ICI-D1542, A THROMBOXANE A2 SYNTHASE INHIBITOR AND TP RECEPTOR ANTAGONIST, ON COLLAGEN-INDUCED HUMAN PLATELET DEGRANULATION AND AGGREGATION

被引：0

作者：

MENYS, VC ^{[1
]}

机构：

[1] MANCHESTER POLYTECH,DEPT BIOL SCI,MANCHESTER M1 5GD,LANCS,ENGLAND

来源：

BRITISH JOURNAL OF PHARMACOLOGY | 1992年 / 107卷

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：P130 / P130

页数：1

共 28 条

[21] INHIBITION OF ANTIGEN-INDUCED AIRWAY HYPERRESPONSIVENESS IN RATS - EFFECTS OF OZAGREL (A THROMBOXANE A(2) SYNTHASE INHIBITOR) AND OF CV-3988 (A PLATELET-ACTIVATING-FACTOR ANTAGONIST)
MISAWA, M
CHIBA, Y
RESEARCH COMMUNICATIONS IN CHEMICAL PATHOLOGY AND PHARMACOLOGY, 1994, 84 (03): : 341 - 349
[22] Effects of KP-496, a novel dual antagonist for cysteinyl leukotriene receptor (CysLT1R) and thromboxane A2 receptor (TP), on porcine pancreas elastase induced emphysema in mice
Kurokawa, S.
Okuda, T.
Amakawa, M.
Suda, M.
Murata, T.
Hiyama, Y.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 119 (01) : S245 - S245
[23] THROMBOXANE SYNTHASE INHIBITION CAUSES RE-DIRECTION OF PROSTAGLANDIN ENDOPEROXIDES TO PROSTAGLANDIN-D2 DURING COLLAGEN STIMULATED AGGREGATION OF HUMAN-PLATELET RICH PLASMA
ORCHARD, MA
WADDELL, KA
LEWIS, PJ
BLAIR, IA
THROMBOSIS RESEARCH, 1985, 39 (06) : 701 - 710
[24] ANTITHROMBOTIC EFFECTS OF RIDOGREL, A COMBINED THROMBOXANE-A2 SYNTHASE INHIBITOR AND PROSTAGLANDIN ENDOPEROXIDE-RECEPTOR ANTAGONIST, IN A PLATELET-MEDIATED CORONARY-ARTERY OCCLUSION PREPARATION IN THE DOG
YASUDA, T
GOLD, HK
YAOTIA, H
GUERRERO, JL
HOLT, RE
FALLON, JT
LEINBACH, RC
COLLEN, D
CORONARY ARTERY DISEASE, 1991, 2 (10) : 1103 - 1110
[25] THE EFFECTS OF AN ORAL THROMBOXANE TP RECEPTOR ANTAGONIST BAY U-3405, ON PROSTAGLANDIN D2-INDUCED AND HISTAMINE-INDUCED BRONCHOCONSTRICTION IN ASTHMA, AND RELATIONSHIP TO PLASMA DRUG CONCENTRATIONS
JOHNSTON, SL
BARDIN, PG
HARRISON, J
RITTER, W
JOUBERT, JR
HOLGATE, ST
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 34 (05) : 402 - 408
[26] EFFECT OF RIDOGREL, A COMBINED THROMBOXANE A2 SYNTHASE INHIBITOR PROSTAGLANDIN ENDOPEROXIDE RECEPTOR ANTAGONIST, ON THE LYSIS OF PLATELET-RICH CORONARY ARTERIAL THROMBI WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR IN A CANINE MODEL
COLLEN, D
MASUDA, M
LU, HR
FLAMENG, W
VERHEYEN, A
DECLERCK, F
GOLD, HK
FIBRINOLYSIS, 1992, 6 (01) : 7 - 15
[27] Pharmacological characterization of N-tert-butyl-N′-[2-(4′-methylphenylamino)-5-nitrobenzenesulfonyl]urea(BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time
Dogné, JM
Hanson, J
de Leval, X
Kolh, P
Tchana-Sato, V
de Leval, L
Rolin, S
Ghuysen, A
Segers, P
Lambermont, B
Masereel, B
Pirotte, B
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 309 (02): : 498 - 505
[28] THE DIHYDROPYRIDINE CALCIUM-CHANNEL AGONIST, BAY K 8644, AND THE ANTAGONIST, NIFEDIPINE, INHIBIT U46619-INDUCED HUMAN-PLATELET ACTIVATION BY COMPETITIVE-BINDING TO THE THROMBOXANE A2/PGH2 RECEPTOR
JOHNSON, GJ
DUNLOP, PC
LEIS, LA
FROM, AHL
THROMBOSIS AND HAEMOSTASIS, 1987, 58 (01) : 262 - 262

← 1 2 3 →